Advertisement

Kidney Disease Following Hematopoietic Stem Cell Transplantation

  • Ala Abudayyeh
    Affiliations
    Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX
    Search for articles by this author
  • Rimda Wanchoo
    Correspondence
    Address correspondence to Rimda Wanchoo, MD, Division of Kidney Disease and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 100 Community Drive, Great Neck, NY 11021.
    Affiliations
    Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
    Search for articles by this author
      Hematopoietic stem cell transplantation (SCT) provides a curative option for the treatment of several malignancies. Its growing use is associated with an increased burden of kidney disease. Acute kidney injury is usually seen within the first 100 days of transplantation and has an incidence ranging between 12 and 73%, with the highest rate in myeloablative allogeneic SCT. A large subset of patients after SCT develop chronic kidney disease. They can be broadly classified into thrombotic microangiopathy, nephrotic syndrome, and calcineurin toxicity. Dialysis requirement after SCT is associated with mortality exceeding 80%. Given the higher morbidity and mortality related to development kidney disease, nephrologists need to be aware of the various causes and best treatment options.

      Graphical abstract

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Copelan E.A.
        Hematopoietic stem-cell transplantation.
        N Engl J Med. 2006; 354: 1813-1826
        • Gratwohl A.
        • Hermans J.
        • Goldman J.M.
        • et al.
        Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
        Lancet. 1998; 352: 1087-1092
        • D'Souza A.
        • Fretham C.
        • Lee S.J.
        • et al.
        Current Use of and Trends in hematopoietic cell transplantation in the United States.
        Biol Blood Marrow Transplant. 2020; 26: e177-e182
        • Sorror M.L.
        • Maris M.B.
        • Storb R.
        • et al.
        Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
        Blood. 2005; 106: 2912-2919
        • Cohen E.P.
        Renal failure after bone-marrow transplantation.
        Lancet. 2001; 357: 6-7
        • Parikh C.R.
        • Schrier R.W.
        • Storer B.
        • et al.
        Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
        Am J Kidney Dis. 2005; 45: 502-509
        • Liu H.
        • Li Y.F.
        • Liu B.C.
        • et al.
        A multicenter, retrospective study of acute kidney injury in adult patients with nonmyeloablative hematopoietic SCT.
        Bone Marrow Transplant. 2010; 45: 153-158
        • Ando M.
        • Mori J.
        • Ohashi K.
        • et al.
        A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT.
        Bone Marrow Transplant. 2010; 45: 1427-1434
        • Caliskan Y.
        • Besisik S.K.
        • Sargin D.
        • Ecder T.
        Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation.
        Bone Marrow Transplant. 2006; 38: 141-147
        • Ataei S.
        • Hadjibabaie M.
        • Moslehi A.
        • et al.
        A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.
        Hematol Oncol. 2015; 33: 67-74
        • Kang S.H.
        • Park H.S.
        • Sun I.O.
        • et al.
        Changes in renal function in long-term survivors of allogeneic hematopoietic stem-cell transplantation: single-center experience.
        Clin Nephrol. 2012; 77: 225-230
        • Abramson M.
        • Gutgarts V.
        • Zheng J.
        • et al.
        Acute kidney injury in the modern Era of allogeneic hematopoietic stem cell transplantation.
        Clin J Am Soc Nephrol. 2021; 16: 1318-1327
        • Lopes J.A.
        • Jorge S.
        • Neves M.
        Acute kidney injury in HCT: an update.
        Bone Marrow Transplant. 2016; 51: 755-762
        • Hingorani S.
        • Finn L.S.
        • Pao E.
        • et al.
        Urinary elafin and kidney injury in hematopoietic cell transplant recipients.
        Clin J Am Soc Nephrol. 2015; 10: 12-20
        • Laskin B.L.
        • Nehus E.
        • Goebel J.
        • Furth S.
        • Davies S.M.
        • Jodele S.
        Estimated versus measured glomerular filtration rate in children before hematopoietic cell transplantation.
        Biol Blood Marrow Transplant. 2014; 20: 2056-2061
        • Waszczuk-Gajda A.
        • Lewandowski Z.
        • Drozd-Sokolowska J.
        • et al.
        Autologous peripheral blood stem cell transplantation in dialysis-dependent multiple myeloma patients-DAUTOS Study of the Polish Myeloma Study Group.
        Eur J Haematol. 2018; 101: 475-485
        • Firkin F.
        • Hill P.A.
        • Dwyer K.
        • Gock H.
        Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation.
        Am J Kidney Dis. 2004; 44: 551-555
        • Mahindra A.
        • Hari P.
        • Fraser R.
        • et al.
        Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.
        Bone Marrow Transplant. 2017; 52: 1616-1622
        • Augeul-Meunier K.
        • Chretien M.L.
        • Stoppa A.M.
        • et al.
        Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC.
        Bone Marrow Transplant. 2018; 53: 749-755
        • Antlanger M.
        • Dust T.
        • Reiter T.
        • et al.
        Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
        Bmc Cancer. 2018; 18: 1008
        • Sweiss K.
        • Culos K.
        • Patel S.
        • Oh A.L.
        • Rondelli D.
        • Patel P.R.
        Melphalan 200 Mg/m2 in patients with renal impairment is associated with increased short term toxicity but improved response and longer treatment-free survival.
        Blood. 2015; 126
        • Knudsen L.M.
        • Nielsen B.
        • Gimsing P.
        • Geisler C.
        Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure.
        Eur J Haematol. 2005; 75: 27-33
        • Badros A.
        • Barlogie B.
        • Siegel E.
        • et al.
        Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
        Br J Haematol. 2001; 114: 822-829
        • Gertz M.A.
        • Lacy M.Q.
        • Dispenzieri A.
        • et al.
        Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma.
        Bone Marrow Transplant. 2007; 39: 605-611
        • St Bernard R.
        • Chodirker L.
        • Masih-Khan E.
        • et al.
        Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.
        Bone Marrow Transplant. 2015; 50: 95-99
        • Carlson K.
        Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival.
        Bone Marrow Transplant. 2005; 35: 985-990
        • Raab M.S.
        • Breitkreutz I.
        • Hundemer M.
        • et al.
        The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
        Haematologica. 2006; 91: 1555-1558
        • El Fakih R.
        • Fox P.
        • Popat U.
        • et al.
        Autologous hematopoietic stem cell transplantation in dialysis-dependent myeloma patients.
        Cl Lymph Myelom Leuk. 2015; 15: 472-476
        • Parikh G.C.
        • Amjad A.I.
        • Saliba R.M.
        • et al.
        Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.
        Biol Blood Marrow Transplant. 2009; 15: 812-816
        • Balsam L.
        • Saad C.
        • Arsene C.
        • Fogel J.
        Impact of autologous stem cell transplantation on blood Pressure and renal function in multiple myeloma patients.
        J Natl Med Assoc. 2017; 109 (Autumn): 182-191
        • Barker J.N.
        • Kurtzberg J.
        • Ballen K.
        • et al.
        Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies.
        Biol Blood Marrow Transplant. 2017; 23: 882-896
        • Takahashi S.
        • Iseki T.
        • Ooi J.
        • et al.
        Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies.
        Blood. 2004; 104: 3813-3820
        • Abudayyeh A.
        • Hamdi A.
        • Abdelrahim M.
        • et al.
        Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients.
        Transplant Infect Dis. 2017; 19: e12632
        • Sanz J.
        • Sanz G.
        • Jimenez C.
        • et al.
        CMV infection and disease in adult patients undergoing unrelated donor cord blood transplantation (UD-CBT).
        Blood. 2003; 102: 476b
        • Mae H.
        • Ooi J.
        • Takahashi S.
        • et al.
        Acute kidney injury after myeloablative cord blood transplantation in adults: the efficacy of strict monitoring of vancomycin serum trough concentrations.
        Transplant Infect Dis. 2013; 15: 181-186
        • Mae H.
        • Ooi J.
        • Takahashi S.
        • et al.
        Early renal injury after myeloablative cord blood transplantation in adults.
        Leuk Lymphoma. 2008; 49: 538-542
        • Bayraktar U.D.
        • de Lima M.
        • Saliba R.M.
        • et al.
        Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
        Biol Blood Marrow Transplant. 2013; 19: 898-903
        • Glezerman I.G.
        • Devlin S.
        • Maloy M.
        • et al.
        Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants.
        Bone Marrow Transplant. 2017; 52: 733-738
        • Spitzer T.R.
        Engraftment syndrome following hematopoietic stem cell transplantation.
        Bone Marrow Transplant. 2001; 27: 893-898
        • Maiolino A.
        • Biasoli I.
        • Lima J.
        • Portugal A.C.
        • Pulcheri W.
        • Nucci M.
        Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria.
        Bone Marrow Transplant. 2003; 31: 393-397
        • Oyama Y.
        • Cohen B.
        • Traynor A.
        • Brush M.
        • Rodriguez J.
        • Burt R.K.
        Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis.
        Bone Marrow Transplant. 2002; 29: 81-85
        • Benoit S.W.
        • Goldstein S.L.
        • Dahale D.S.
        • et al.
        Reduction in nephrotoxic Antimicrobial exposure decreases associated acute kidney injury in pediatric hematopoietic stem cell transplant patients.
        Biol Blood Marrow Transplant. 2019; 25: 1654-1658
        • Hingorani S.R.
        • Guthrie K.
        • Batchelder A.
        • et al.
        Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors.
        Kidney Int. 2005; 67: 272-277
        • Goldstein S.L.
        • Mottes T.
        • Simpson K.
        • et al.
        A sustained quality improvement program reduces nephrotoxic medication-associated acute kidney injury.
        Kidney Int. 2016; 90: 212-221
        • Moffett B.S.
        • Goldstein S.L.
        Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children.
        Clin J Am Soc Nephrol. 2011; 6: 856-863
        • Hingorani S.
        • Guthrie K.A.
        • Schoch G.
        • Weiss N.S.
        • McDonald G.B.
        Chronic kidney disease in long-term survivors of hematopoietic cell transplant.
        Bone Marrow Transplant. 2007; 39: 223-229
        • Changsirikulchai S.
        • Myerson D.
        • Guthrie K.A.
        • McDonald G.B.
        • Alpers C.E.
        • Hingorani S.R.
        Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.
        Clin J Am Soc Nephrol. 2009; 4: 345-353
        • Biedermann B.C.
        • Sahner S.
        • Gregor M.
        • et al.
        Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease.
        Lancet. 2002; 359: 2078-2083
        • Parikh C.R.
        • Coca S.G.
        Acute renal failure in hematopoietic cell transplantation.
        Kidney Int. 2006; 69: 430-435
        • Couriel D.
        • Caldera H.
        • Champlin R.
        • Komanduri K.
        Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management.
        Cancer. 2004; 101: 1936-1946
        • Krenger W.
        • Hill G.R.
        • Ferrara J.L.
        Cytokine cascades in acute graft-versus-host disease.
        Transplantation. 1997; 64: 553-558
        • Cutler C.
        • Stevenson K.
        • Kim H.T.
        • et al.
        Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
        Blood. 2008; 112: 4425-4431
        • Cheuk D.K.
        • Wang P.
        • Lee T.L.
        • et al.
        Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation.
        Bone Marrow Transplant. 2007; 40: 935-944
        • Coppell J.A.
        • Richardson P.G.
        • Soiffer R.
        • et al.
        Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
        Biol Blood Marrow Transplant. 2010; 16: 157-168
        • McDonald G.B.
        • Sandmaier B.M.
        • Mielcarek M.
        • et al.
        Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts.
        Ann Intern Med. 2020; 172: 229-239
        • Richardson P.G.
        • Soiffer R.J.
        • Antin J.H.
        • et al.
        Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
        Biol Blood Marrow Transplant. 2010; 16: 1005-1017
        • Schröder H.
        Defibrotide protects endothelial cells, but not L929 tumour cells, from tumour necrosis factor-alpha-mediated cytotoxicity.
        J Pharm Pharmacol. 1995; 47: 250-252
        • Bollard C.M.
        • Heslop H.E.
        T cells for viral infections after allogeneic hematopoietic stem cell transplant.
        Blood. 2016; 127: 3331-3340
        • Hingorani S.
        Renal complications of hematopoietic-cell transplantation.
        N Engl J Med. 2016; 374: 2256-2267
        • Cesaro S.
        • Dalianis T.
        • Hanssen Rinaldo C.
        • et al.
        ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients.
        J Antimicrob Chemother. 2018; 73: 12-21
        • Abudayyeh A.
        • Hamdi A.
        • Lin H.
        • et al.
        Symptomatic BK virus infection is associated with kidney function decline and poor overall survival in allogeneic hematopoietic stem cell recipients.
        Am J Transplant. 2016; 16: 1492-1502
        • Imlay H.
        • Xie H.
        • Leisenring W.M.
        • et al.
        Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation.
        Blood Adv. 2020; 4: 617-628
        • Rorije N.M.
        • Shea M.M.
        • Satyanarayana G.
        • et al.
        BK virus disease after allogeneic stem cell transplantation: a cohort analysis.
        Biol Blood Marrow Transplant. 2014; 20: 564-570
        • Bruno B.
        • Zager R.A.
        • Boeckh M.J.
        • et al.
        Adenovirus nephritis in hematopoietic stem-cell transplantation.
        Transplantation. 2004; 77: 1049-1057
        • Tzannou I.
        • Papadopoulou A.
        • Naik S.
        • et al.
        Off-the-Shelf virus-specific T cells to treat BK virus, human Herpesvirus 6, Cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation.
        J Clin Oncol. 2017; 35: 3547-3557
        • Olson A.
        • Lin R.
        • Marin D.
        • et al.
        Third-party BK virus-specific cytotoxic T lymphocyte therapy for hemorrhagic cystitis following Allotransplantation.
        J Clin Oncol. 2021; 39: 2710-2719
        • Rondon G.
        • Saliba R.M.
        • Chen J.
        • et al.
        Impact of fluid overload as new toxicity category on hematopoietic stem cell transplantation outcomes.
        Biol Blood Marrow Transplant. 2017; 23: 2166-2171
        • Schrier R.W.
        • Parikh C.R.
        Comparison of renal injury in myeloablative autologous, myeloablative allogeneic and non-myeloablative allogeneic haematopoietic cell transplantation.
        Nephrol Dial Transplant. 2005; 20: 678-683
        • Parikh C.R.
        • McSweeney P.A.
        • Korular D.
        • et al.
        Renal dysfunction in allogeneic hematopoietic cell transplantation.
        Kidney Int. 2002; 62: 566-573
        • Parikh C.R.
        • Sandmaier B.M.
        • Storb R.F.
        • et al.
        Acute renal failure after nonmyeloablative hematopoietic cell transplantation.
        J Am Soc Nephrol. 2004; 15: 1868-1876
        • Parikh C.R.
        • McSweeney P.
        • Schrier R.W.
        Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant.
        Kidney Int. 2005; 67: 1999-2005
        • Nakamura M.
        • Fujii N.
        • Shimizu K.
        • et al.
        Long-term outcomes in patients treated in the intensive care unit after hematopoietic stem cell transplantation.
        Int J Hematol. 2018; 108: 622-629
        • Cekdemir D.
        • Atasoyu E.M.
        • Gulbas Z.
        Acute kidney injury developing in the early period in the patients undergoing autolog and allogeneic hematopoietic stem cell transplantation.
        Nephrol Dial Transplant. 2018; 33: i25
        • Hahn T.
        • Rondeau C.
        • Shaukat A.
        • et al.
        Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients.
        Bone Marrow Transplant. 2003; 32: 405-410
        • Wolff D.
        • Wilhelm S.
        • Hahn J.
        • et al.
        Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
        Bone Marrow Transplant. 2006; 38: 445-451
        • Ellis M.J.
        • Parikh C.R.
        • Inrig J.K.
        • Kanbay M.
        • Patel U.D.
        Chronic kidney disease after hematopoietic cell transplantation: a systematic review.
        Am J Transplant. 2008; 8: 2378-2390
        • Hingorani S.
        Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment.
        J Am Soc Nephrol. 2006; 17: 1995-2005
        • Lugthart G.
        • Jordans C.C.E.
        • de Pagter A.P.J.
        • et al.
        Chronic kidney disease ten years after pediatric allogeneic hematopoietic stem cell transplantation.
        Kidney Int. 2021; 0
        • Jo T.
        • Arai Y.
        • Kondo T.
        • et al.
        Chronic kidney disease in long-term survivors after allogeneic hematopoietic stem cell transplantation: retrospective analysis at a single institute.
        Biol Blood Marrow Transplant. 2017; 23
        • Ando M.
        • Ohashi K.
        • Akiyama H.
        • et al.
        Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors.
        Nephrol Dial Transplant. 2009; 25: 278-282
        • Gutierrez-Garcia G.
        • Villarreal J.
        • Garrote M.
        • et al.
        Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis.
        Bone Marrow Transplant. 2020; 55: 1264-1271
        • Farhadfar N.
        • Dias A.
        • Wang T.
        • et al.
        Impact of Pretransplantation renal dysfunction on outcomes after allogeneic hematopoietic cell transplantation.
        Transplant Cell Ther. 2021; 27: 410-422
        • Hingorani S.
        • Pao E.
        • Stevenson P.
        • et al.
        Changes in glomerular filtration rate and impact on long-term survival among adults after hematopoietic cell transplantation: a Prospective cohort study.
        Clin J Am Soc Nephrol. 2018; 13: 866-873
        • Humphreys B.D.
        Onco-nephrology: kidney disease in the cancer patient: introduction.
        Semin Nephrol. 2010; 30: 531-533
        • Hingorani S.
        • Gooley T.
        • Pao E.
        • Sandmaier B.
        • McDonald G.
        Urinary cytokines after HCT: evidence for renal inflammation in the pathogenesis of proteinuria and kidney disease.
        Bone Marrow Transplant. 2014; 49: 403-409
        • Moake J.L.
        Thrombotic microangiopathies.
        N Engl J Med. 2002; 347: 589-600
        • Jodele S.
        • Davies S.M.
        • Lane A.
        • et al.
        Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults.
        Blood. 2014; 124: 645-653
        • Labrador J.
        • López-Corral L.
        • López-Godino O.
        • et al.
        Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
        Bone Marrow Transplant. 2014; 49: 684-690
        • Cho B.S.
        • Yahng S.A.
        • Lee S.E.
        • et al.
        Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation.
        Transplantation. 2010; 90: 918-926
        • Ho V.T.
        • Cutler C.
        • Carter S.
        • et al.
        Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.
        Biol Blood Marrow Transplant. 2005; 11: 571-575
        • Ruutu T.
        • Barosi G.
        • Benjamin R.J.
        • et al.
        Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.
        Haematologica. 2007; 92: 95-100
        • Chan G.S.
        • Lam M.F.
        • Au W.Y.
        • et al.
        Clinicopathologic analysis of renal biopsies after haematopoietic stem cell transplantation.
        Nephrology. 2008; 13: 322-330
        • Siami K.
        • Kojouri K.
        • Swisher K.K.
        • Selby G.B.
        • George J.N.
        • Laszik Z.G.
        Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: an autopsy study.
        Transplantation. 2008; 85: 22-28
        • Moore I.
        • Strain L.
        • Pappworth I.
        • et al.
        Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.
        Blood. 2010; 115: 379-387
        • Qi J.
        • Wang J.
        • Chen J.
        • et al.
        Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation.
        Ann Hematol. 2017; 96: 1849-1855
        • Kanamori H.
        • Takaishi Y.
        • Takabayashi M.
        • et al.
        Clinical significance of fragmented red cells after allogeneic bone marrow transplantation.
        Int J Hematol. 2003; 77: 180-184
        • Wanchoo R.
        • Bayer R.L.
        • Bassil C.
        • Jhaveri K.D.
        Emerging Concepts in hematopoietic stem cell transplantation-associated renal thrombotic microangiopathy and Prospects for new treatments.
        Am J Kidney Dis. 2018; 72: 857-865
        • Min C.K.
        • Kim S.Y.
        • Lee M.J.
        • et al.
        Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.
        Bone Marrow Transplant. 2006; 38: 149-156
        • Dietrich S.
        • Falk C.S.
        • Benner A.
        • et al.
        Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment.
        Biol Blood Marrow Transplant. 2013; 19: 22-27
        • Luft T.
        • Dietrich S.
        • Falk C.
        • et al.
        Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system.
        Blood. 2011; 118: 1685-1692
        • Vander Lugt M.T.
        • Braun T.M.
        • Hanash S.
        • et al.
        ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
        N Engl J Med. 2013; 369: 529-539
        • Zeiser R.
        • Blazar B.R.
        Pathophysiology of chronic graft-versus-host disease and therapeutic targets.
        N Engl J Med. 2017; 377: 2565-2579
        • Cho B.S.
        • Min C.K.
        • Eom K.S.
        • et al.
        Clinical impact of thrombotic microangiopathy on the outcome of patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
        Bone Marrow Transplant. 2008; 41
        • Laskin B.L.
        • Goebel J.
        • Davies S.M.
        • Jodele S.
        Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
        Blood. 2011; 118: 1452-1462
        • Oran B.
        • Donato M.
        • Aleman A.
        • et al.
        Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment.
        Biol Blood Marrow Transplant. 2007; 13: 469-477
        • Willems E.
        • Baron F.
        • Seidel L.
        • Frère P.
        • Fillet G.
        • Beguin Y.
        Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning.
        Bone Marrow Transplant. 2010; 45: 689-693
        • Nguyen L.
        • Terrell D.R.
        • Duvall D.
        • Vesely S.K.
        • George J.N.
        Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008.
        Transfusion. 2009; 49: 392-394
        • Thachil J.
        The role for adjunctive treatment to plasma exchange in thrombotic thrombocytopenic purpura.
        Nephrol Dial Transplant. 2008; 23: 2701-2702
        • Khosla J.
        • Yeh A.C.
        • Spitzer T.R.
        • Dey B.R.
        Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.
        Bone Marrow Transplant. 2018; 53: 129-137
        • Au W.Y.
        • Ma E.S.
        • Lee T.L.
        • et al.
        Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab.
        Br J Haematol. 2007; 137: 475-478
        • Carella A.M.
        • D’Arena G.
        • Greco M.M.
        • Nobile M.
        • Cascavilla N.
        Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura.
        Bone Marrow Transplant. 2008; 41: 1063-1065
        • Marr H.
        • McDonald E.J.
        • Merriman E.
        • et al.
        Successful treatment of transplant-associated microangiopathy with rituximab.
        N Z Med J. 2009; 122: 72-74
        • Jodele S.
        • Bleesing J.J.
        • Mehta P.A.
        • et al.
        Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation.
        Pediatr Transplant. 2012; 16: E39-E42
        • de Fontbrune F.S.
        • Galambrun C.
        • Sirvent A.
        • et al.
        Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC.
        Transplantation. 2015; 99: 1953-1959
        • Dhakal P.
        • Giri S.
        • Pathak R.
        • Bhatt V.R.
        Eculizumab in transplant-associated thrombotic microangiopathy.
        Clin Appl Thromb Hemost. 2017; 23: 175-180
        • Jodele S.
        • Dandoy C.E.
        • Lane A.
        • et al.
        Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
        Blood. 2020; 135: 1049-1057
        • Rudoni J.
        • Jan A.
        • Hosing C.
        • Aung F.
        • Yeh J.
        Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients.
        Eur J Haematol. 2018; 101: 389-398
        • Corti P.
        • Uderzo C.
        • Tagliabue A.
        • et al.
        Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation.
        Bone Marrow Transplant. 2002; 29: 542-543
        • Uderzo C.
        • Bonanomi S.
        • Busca A.
        • et al.
        Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
        Transplantation. 2006; 82: 638-644
        • Dieterle A.
        • Gratwohl A.
        • Nizze H.
        • et al.
        Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients.
        Transplantation. 1990; 49: 1093-1099
        • Jensen R.R.
        • Healy R.M.
        • Ford C.D.
        • et al.
        Amlodipine and calcineurin inhibitor-induced nephrotoxicity following allogeneic hematopoietic stem cell transplant.
        Clin Transplant. 2019; 33: e13633
        • Ruiz-Arguelles G.J.
        • Gomez-Almaguer D.
        Nephrotic syndrome after non-myeloablative stem cell transplantation.
        Br J Haematol. 2006; 132
        • Srinivasan R.
        • Balow J.E.
        • Sabnis S.
        • et al.
        Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation.
        Br J Haematol. 2005; 131
        • Brukamp K.
        • Doyle A.M.
        • Bloom R.D.
        • Bunin N.
        • Tomaszewski J.E.
        • Cizman B.
        Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease?.
        Clin J Am Soc Nephrol. 2006; 1: 685-694
        • Kawakami K.
        • Watanabe Y.
        • Mukai K.
        • et al.
        Nephrotic syndrome with extensive mesangiolysis as a clinical manifestation of chronic graft-versus-host disease (GVHD).
        Int J Hematol. 2005; 82: 270-272
        • Reddy P.
        • Johnson K.
        • Uberti J.P.
        • et al.
        Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
        Bone Marrow Transplant. 2006; 38: 351-357
        • Hu S.L.
        The role of graft-versus-host disease in haematopoietic cell transplantation-associated glomerular disease.
        Nephrol Dial Transplant. 2011; 26: 2025-2031
        • Kemper M.J.
        • Güngör T.
        • Halter J.
        • Schanz U.
        • Neuhaus T.J.
        Favorable long-term outcome of nephrotic syndrome after allogeneic hematopoietic stem cell transplantation.
        Clin Nephrol. 2007; 67: 5-11
        • Suehiro T.
        • Masutani K.
        • Yokoyama M.
        • et al.
        Diffuse proliferative glomerulonephritis after bone marrow transplantation.
        Clin Nephrol. 2002; 58: 231-237
        • Murphy W.J.
        Revisiting graft-versus-host disease models of autoimmunity: new insights in immune regulatory processes.
        J Clin Invest. 2000; 106: 745-747
        • Bonilla M.
        • Bijol V.
        • Wanchoo R.
        • Keyzner A.
        • Jhaveri K.D.
        The Case | Proteinuria in a patient with hematopoietic stem cell transplantation.
        Kidney Int. 2021; 99: 1249-1250
        • Kudose S.
        • Sekulic M.
        • Mehring C.J.
        • et al.
        NELL1-Associated membranous Glomerulopathy after hematopoietic stem cell transplantation.
        Kidney Int Rep. 2021; 6: 1992-1995
        • Nasr S.H.
        • Leung N.
        • Said S.M.
        • et al.
        Membranous nephropathy with extensive tubular basement membrane deposits following allogeneic hematopoietic cell transplant: a report of 5 cases.
        Am J Kidney Dis. 2021; https://doi.org/10.1053/j.ajkd.2021.07.021
        • Niscola P.
        • Tendas A.
        • Luo X.D.
        • et al.
        The management of membranous glomerulopathy in allogeneic stem cells transplantation: updated literature.
        Cardiovasc Hematol Agents Med Chem. 2013; 11: 67-76
        • Wong E.
        • Lasica M.
        • He S.Z.
        • et al.
        Nephrotic syndrome as a complication of chronic graft-versus-host disease after allogeneic haemopoietic stem cell transplantation.
        Intern Med J. 2016; 46: 737-741
        • Cohen E.P.
        • Drobyski W.R.
        • Moulder J.E.
        Significant increase in end-stage renal disease after hematopoietic stem cell transplantation.
        Bone Marrow Transplant. 2007; 39: 571-572
        • Shadman M.
        • Hingorani S.
        • Lanum S.A.
        • et al.
        Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis - a single institution experience.
        Leuk Lymphoma. 2017; 58: 740-742
        • Li A.Y.
        • Atenafu E.G.
        • Bernard R.
        • et al.
        Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras.
        Bone Marrow Transplant. 2020; 55: 578-585
        • Lee C.K.
        • Zangari M.
        • Barlogie B.
        • et al.
        Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant.
        Bone Marrow Transplant. 2004; 33: 823-828
        • Nath C.E.
        • Trotman J.
        • Tiley C.
        • et al.
        High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
        Br J Clin Pharmacol. 2016; 82: 149-159
        • Batalini F.
        • Econimo L.
        • Quillen K.
        • et al.
        High-dose melphalan and stem cell transplantation in patients on dialysis due to Immunoglobulin light-chain Amyloidosis and monoclonal Immunoglobulin deposition disease.
        Biol Blood Marrow Transplant. 2018; 24: 127-132
        • Morita K.
        • Ashizawa M.
        • Toda Y.
        • et al.
        Salvage chemotherapy followed by autologous stem-cell transplantation using targeted busulfan for refractory diffuse large B-cell lymphoma with dialysis-dependent end-stage renal disease.
        Clin Lymphoma Myeloma Leuk. 2020; 20: e92-e96
        • Butcher J.A.
        • Hariharan S.
        • Adams M.B.
        • Johnson C.P.
        • Roza A.M.
        • Cohen E.P.
        Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression.
        Clin Transplant. 1999; 13: 330-335
        • Hamawi K.
        • De Magalhaes-Silverman M.
        • Bertolatus J.A.
        Outcomes of renal transplantation following bone marrow transplantation.
        Am J Transplant. 2003; 3: 301-305
        • Koenecke C.
        • Hertenstein B.
        • Schetelig J.
        • et al.
        Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMT.
        Am J Transplant. 2010; 10: 1897-1906
        • Faraci M.
        • Bertaina A.
        • Dalissier A.
        • et al.
        Solid organ transplantation after hematopoietic stem cell transplantation in childhood: a multicentric retrospective survey.
        Am J Transplant. 2019; 19: 1798-1805
        • Jodele S.
        • Laskin B.L.
        • Dandoy C.E.
        • et al.
        A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.
        Blood Rev. 2015; 29: 191-204